Englander Institute for Precision Medicine

Publications

Found 832 results
Author Title Type [ Year(Asc)]
2025
Sternberg CN, Squifflet P, Saad ED, Burdett S, Fisher D, Kurt M, Teitsson S, May JR, Patel MY, Stoeckle M et al..  2025.  Evaluating surrogates for overall survival in the adjuvant treatment of bladder cancer with chemotherapy.. Urol Oncol.
de Bono JS, He M, Shi Z, Nowicka M, Bracarda S, Sternberg CN, Chi KN, Olmos D, Sandhu S, Massard C et al..  2025.  Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial.. Eur Urol.
Rajendran S, Rehani E, Phu W, Zhan Q, Malmsten JE, Meseguer M, Miller KA, Rosenwaks Z, Elemento O, Zaninovic N et al..  2025.  A foundational model for in vitro fertilization trained on 18 million time-lapse images.. Nat Commun. 16(1):6235.
Claridge SE, Nath S, Baum A, Farias R, Cavallo J-A, Rizvi NM, De Boni L, Park E, Granados GLara, Hauesgen M et al..  2025.  Functional genomics pipeline identifies CRL4 inhibition for the treatment of ovarian cancer.. Clin Transl Med. 15(2):e70078.
Borea R, Reduzzi C.  2025.  The growing field of liquid biopsy and its Snowball effect on reshaping cancer management.. J Liq Biopsy. 8:100293.
Petroni G, Galassi C, Gouin KH, Chen H-H, Buqué A, Bloy N, Yamazaki T, Sato A, Beltrán-Visiedo M, Campia G et al..  2025.  IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2- breast cancer via CX3CR1+ macrophages.. Nat Cancer.
Hissong E, Bhinder B, Kim J, Ohara K, Ravichandran H, Assaad MAl, Elsoukkary S, Shusterman M, Khan U, Eng KWha et al..  2025.  Integrative transcriptomic and single-cell protein characterization of colorectal carcinoma delineates distinct tumor immune microenvironments associated with overall survival.. Pathol Res Pract. 273:156150.
Mizuno K, Ku S-Y, Venkadakrishnan VBalaji, Bakht MK, Sigouros M, Chan J, Trigos A, Driskill JH, Manohar J, King A et al..  2025.  Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer.. Nat Commun. 16(1):5543.
Barton BM, Son F, Verma A, Bal SKumar, Tang Q, Wang R, Umphred-Wilson K, Khan R, Trichka J, Dong H et al..  2025.  IRE1α-XBP1 safeguards hematopoietic stem and progenitor cells by restricting pro-leukemogenic gene programs.. Nat Immunol.
Rowdo FPMadorsky, Martini R, Ackermann SE, Tang CP, Tranquille M, Irizarry A, Us I, Alawa O, Moyer JE, Sigouros M et al..  2025.  Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition.. Cancer Res. 85(3):551-566.
Schiavone MLuisa, Scarpitta R, Ravera F, Bleve S, Reduzzi C, Di Cocco F, Dameri M, Zoppoli G, Naccarato AGiuseppe, Nuzzo PVitale et al..  2025.  Liquid biopsy in breast cancer: Redefining precision medicine.. J Liq Biopsy. 9:100312.
Howlader MJ, Rashighi M, Santambrogio L, Lu TT.  2025.  Lymphatic messengers: Non-antigen soluble mediators from diseased tissues to draining lymph nodes.. Curr Opin Immunol. 93:102536.
Guevara D, Shin N, Boiko A, Valiev I, Elsaeed AG, Mosquera JMiguel, Assaad MAl, Manohar J, Sigouros M, Zaichikova A et al..  2025.  Mesonephric Adenocarcinoma in a Young Male Patient.. Anticancer Res. 45(2):619-623.
Chen HJoyce, Gardner EE, Shah Y, Zhang K, Thakur A, Zhang C, Elemento O, Varmus H.  2025.  Metastatic small cell lung cancer arises from TP53/RB1-deficient and MYC overproduction hESC-derived PNECs.. Elife. 13
Tyrakis PA, Kampjut D, Steele GF, H Lindström JG, Chirnomas D, Hopkins BD, Goncalves MD, Mukherjee S, Cantley LC, Maddocks ODK.  2025.  Multi-node inhibition targeting mTORC1, mTORC2 and PI3Kα potently inhibits the PI3K/AKT/mTOR pathway in endometrial and breast cancer models.. Br J Cancer.
Kyei I, Bea VJ, Gyan KK, Adjei E, Stonaker B, Bekele M, Abebe E, Davis M, Boakye A, Boateng R et al..  2025.  Oncologic Anthropology and the African Diaspora: Twenty-Year Anniversary Report, International Center for the Study of Breast Cancer Subtypes (ICSBCS).. Ann Surg Oncol.
Bhinder B, Friedl V, Sethuraman S, Risso D, Chiotti KE, R Mashl J, Ellrott KP, Lee JA, Wong CK, Gyan K et al..  2025.  Pan-cancer immune and stromal deconvolution predicts clinical outcomes and mutation profiles.. Sci Rep. 15(1):23921.
Fiore D, Cappelli LVincenzo, Zhaoqi L, Kotlov N, Sorokina M, Phillip J, Zumbo P, Yoffe L, Ghione P, Wang A et al..  2025.  A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities.. Cell Rep Med. :102029.
K Devi SP, Wang E, Jaiswal A, Konieczny P, Kim T-G, Nirschl CJ, Verma A, Liu Y, Milczanowski J, Christo SN et al..  2025.  PD-1 is requisite for skin TRM cell formation and specification by TGFβ.. Nat Immunol. 26(8):1339-1351.
Horne CR, Dite TA, Young SN, Mather LJ, Dagley LF, Johnson JL, Yaron-Barir TM, Huntsman EM, Daly LA, Byrne DP et al..  2025.  "PSKH1 kinase activity is differentially modulated via allosteric binding of Ca²⁺ sensor proteins". Proc Natl Acad Sci U S A. 122(8):e2420961122.
Müller-Dott S, Jaehnig EJ, Munchic KPham, Jiang W, Yaron-Barir TM, Savage SR, Garrido-Rodriguez M, Johnson JL, Lussana A, Petsalaki E et al..  2025.  Publisher Correction: Comprehensive evaluation of phosphoproteomic-based kinase activity inference.. Nat Commun. 16(1):6591.
Laurent P-A, Andre F, Bobard A, Deandreis D, Demaria S, Depil S, Eichmüller SB, Fernandez-Palomo C, Foijer F, Galluzzi L et al..  2025.  Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7th immunorad conference.. Oncoimmunology. 14(1):2432726.
Nagar H, Diven MA, Rippon B, Barbieri CE, Hu JC, Scherr DS, Yadav P, Tshering L, Chandrasekhar S, Wolfe S et al..  2025.  A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks (SHORTER): Acute Genitourinary and Gastrointestinal Patient-reported Outcomes at a Single Institution.. Eur Urol Oncol.
Akinsanya K, AlQuraishi M, Boija A, Chodera J, Cichońska A, Ghassemi M, Head M, Jin W, Kibbe WA, Krogan N et al..  2025.  Redefining druggable targets with artificial intelligence.. Nat Biotechnol.
Chukwu W, Lee S, Crane A, Zhang S, Webster S, Dakhama O, Mittra I, Rauert C, Imielinski M, Beroukhim R et al..  2025.  A sequence context-based approach for classifying tumor structural variants without paired normal samples.. Cell Rep Methods. :100991.